131 related articles for article (PubMed ID: 16239360)
1. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.
Skerjanec A; Tedesco H; Neumayer HH; Cole E; Budde K; Hsu CH; Schmouder R
J Clin Pharmacol; 2005 Nov; 45(11):1268-78. PubMed ID: 16239360
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Kahan BD; Karlix JL; Ferguson RM; Leichtman AB; Mulgaonkar S; Gonwa TA; Skerjanec A; Schmouder RL; Chodoff L
Transplantation; 2003 Oct; 76(7):1079-84. PubMed ID: 14557756
[TBL] [Abstract][Full Text] [Related]
3. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
[TBL] [Abstract][Full Text] [Related]
4. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
Tedesco-Silva H; Mourad G; Kahan BD; Boira JG; Weimar W; Mulgaonkar S; Nashan B; Madsen S; Charpentier B; Pellet P; Vanrenterghem Y
Transplantation; 2004 Jun; 77(12):1826-33. PubMed ID: 15223899
[TBL] [Abstract][Full Text] [Related]
5. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
Kovarik JM; Schmouder RL; Barilla D; Büche M; Rouilly M; Berthier S; Wang Y; Van Saders C; Mayer T; Gottlieb AB
Ann Pharmacother; 2004; 38(7-8):1153-8. PubMed ID: 15138297
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.
Meno-Tetang GM; Li H; Mis S; Pyszczynski N; Heining P; Lowe P; Jusko WJ
Drug Metab Dispos; 2006 Sep; 34(9):1480-7. PubMed ID: 16751263
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF
Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
[TBL] [Abstract][Full Text] [Related]
8. FTY720: early clinical experience.
Dragun D; Fritsche L; Boehler T; Peters H; Budde K; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):544S-548S. PubMed ID: 15041403
[TBL] [Abstract][Full Text] [Related]
9. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
Kovarik JM; Hartmann S; Bartlett M; Riviere GJ; Neddermann D; Wang Y; Port A; Schmouder RL
Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
[TBL] [Abstract][Full Text] [Related]
10. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.
Budde K; Schmouder RL; Brunkhorst R; Nashan B; Lücker PW; Mayer T; Choudhury S; Skerjanec A; Kraus G; Neumayer HH
J Am Soc Nephrol; 2002 Apr; 13(4):1073-1083. PubMed ID: 11912269
[TBL] [Abstract][Full Text] [Related]
11. The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients.
Westhoff TH; Schmidt S; Glander P; Liefeld L; Martini S; Offermann G; Neumayer HH; Zidek W; van der Giet M; Budde K
Nephrol Dial Transplant; 2007 Aug; 22(8):2354-8. PubMed ID: 17526535
[TBL] [Abstract][Full Text] [Related]
12. A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments.
Suzuki T; Jin MB; Shimamura T; Yamashita K; Taniguchi M; Nomura M; Yokota R; Fukai M; Magata S; Horiuchi H; Fujita M; Nagashima K; Furukawa H; Todo S
Transpl Int; 2004 Nov; 17(10):574-84. PubMed ID: 15592714
[TBL] [Abstract][Full Text] [Related]
13. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
Park SI; Felipe CR; Machado PG; Garcia R; Skerjanec A; Schmouder R; Tedesco-Silva H; Medina-Pestana JO
Braz J Med Biol Res; 2005 May; 38(5):683-94. PubMed ID: 15917949
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.
Tedesco-Silva H; Pescovitz MD; Cibrik D; Rees MA; Mulgaonkar S; Kahan BD; Gugliuzza KK; Rajagopalan PR; Esmeraldo Rde M; Lord H; Salvadori M; Slade JM;
Transplantation; 2006 Dec; 82(12):1689-97. PubMed ID: 17198261
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of fingolimod phosphate in healthy participants.
Wu K; Mercier F; David OJ; Schmouder RL; Looby M
J Clin Pharmacol; 2012 Jul; 52(7):1054-68. PubMed ID: 22110161
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients.
Lukas JC; Suárez AM; Valverde MP; Calvo MV; Lanao JM; Calvo R; Suarez E; Gil AD
J Clin Pharm Ther; 2005 Dec; 30(6):549-57. PubMed ID: 16336287
[TBL] [Abstract][Full Text] [Related]
18. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L;
Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034
[TBL] [Abstract][Full Text] [Related]
19. FTY720 (fingolimod) in renal transplantation.
Budde K; Schütz M; Glander P; Peters H; Waiser J; Liefeldt L; Neumayer HH; Böhler T
Clin Transplant; 2006; 20 Suppl 17():17-24. PubMed ID: 17100697
[TBL] [Abstract][Full Text] [Related]
20. FTY720 immunomodulation: optimism for improved transplant regimens.
Ferguson R
Transplant Proc; 2004 Mar; 36(2 Suppl):549S-553S. PubMed ID: 15041404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
